Lexington-Fayette

No, new studies show that the J & J vaccine is “ineffective” against delta variants – Lexington-Fayette, Kentucky

Lexington-Fayette, Kentucky 2021-07-21 10:35:22 –

San Diego — A New research The Johnson & Johnson COVID-19 vaccine released on Tuesday suggests that antibody protection against delta mutants is significantly weaker than in the original strain.

However, medical experts say the results are far from evidence that single-dose vaccines are ineffective against real-world mutants.

A survey by a team at New York University caused a surge in headlines of concern on Tuesday.The New York Times was originally Publish the report “J. & J. A single dose of vaccine has no effect on deltas, studies suggest.”

The treatise later changed its title to “J. & J. Vaccines may be less effective against deltas, studies suggest.”

NYU scientists took blood from 10 people vaccinated with the J & J vaccine and placed protective antibodies on the plate. They then introduced various COVID-19 mutants to see how well the antibody blocked them.

On average, the team is about Johnson & Johnson vaccine 7 times weaker For delta variants than the original strain of COVID-19. These results were significantly lower than those seen in people who received the Pfizer or Mothana vaccine.

NYU studies have not yet been peer reviewed.

J & J is the only single-dose COVID-19 vaccine approved for emergency use in the United States. The authors of the paper suggested that those who received the injection could benefit from a second dose.

But outside experts, such as Dr. Peter Chin Hong of the University of California, San Francisco, said it was too early to make that assumption.

“Laboratory-based research cannot always be extrapolated to what is happening in real life,” he said.

This is because vaccines produce more protection than just antibodies. It also trains live cells called “killer T cells” and “helper T cells”. The three branches work together like military branches — Army, Navy, and Air Force.

“What I’ve known about J & J for some time is that protection doesn’t directly track the number of these antibodies,” said Shane Crotti, a professor at the Lahora Institute for Immunology.

During the company’s clinical trials in South Africa, the Johnson & Johnson vaccine was 64% effective against the elusive variant now called the beta variant.

A new NYU study did not measure T cell response, but found that J & J antibodies function against delta in much the same way as against beta. This is a promising clue.

The Johnson & Johnson vaccine “may lose some protection against the case itself, but still has very high protection against bad COVID, hospital-level COVID,” he said.

The single-dose J & J vaccine was approved after the Pfizer and Moderna vaccines, so there was little research on it.

NYU’s work is inconsistent with some of the previous data. According to experts, it could be because the team ran the test within 3 months after the shot on average.

Johnson & Johnson published a study this month that found that antibody levels increased in strength over eight months.

“Like wine, it may get better with age,” said Chin Hong.

For now, experts say there is greater concern about people who have not yet been vaccinated — those who have not been shot account for 99% of hospitalizations and deaths from delta variants.

This story was originally published by Derek Staahl at the Scripps station KGTV In San Diego.



Source link

Back to top button